ALNY (STOCKS)
Alnylam Pharmaceuticals, Inc.
$333.000000
+10.890000 (+3.38%)
Prev close: $322.110000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Yvonne L. Greenstreet
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $44,163.50M
- Employees
- 2,230
- P/E (TTM)
- 138.27
- P/B (TTM)
- 54.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
20
Buy
9
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.82 | $1.15 | -0.3265 | -28.48% |
|
Sep 2025 (Q3)
|
$2.11 | $0.76 | +1.3487 | +177.16% |
|
Jun 2025 (Q2)
|
$-0.51 | $-0.73 | +0.2249 | +30.60% |
|
Mar 2025 (Q1)
|
$-0.44 | $-1.03 | +0.5883 | +57.21% |
Financial Statements
| Revenues | $3.71B |
| Benefits Costs and Expenses | $3.39B |
| Cost Of Revenue | $677.17M |
| Costs And Expenses | $3.21B |
| Gross Profit | $3.04B |
| Nonoperating Income/Loss | -$178.43M |
| Operating Expenses | $2.54B |
| Selling, General, and Administrative Expenses | $1.21B |
| Research and Development | $1.32B |
| Other Operating Expenses | $4.71M |
| Operating Income/Loss | $501.58M |
| Income/Loss From Continuing Operations After Tax | $313.75M |
| Income/Loss From Continuing Operations Before Tax | $323.15M |
| Income Tax Expense/Benefit | $9.41M |
| Income Tax Expense/Benefit, Current | $11.60M |
| Income Tax Expense/Benefit, Deferred | -$2.20M |
| Net Income/Loss | $313.75M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $313.75M |
| Net Income/Loss Available To Common Stockholders, Basic | $313.75M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.39 |
| Diluted Earnings Per Share | $2.33 |
| Basic Average Shares | 131,004,000 |
| Diluted Average Shares | 134,684,000 |
| Assets | $4.97B |
| Current Assets | $4.05B |
| Inventory | $82.72M |
| Other Current Assets | $3.97B |
| Noncurrent Assets | $915.67M |
| Fixed Assets | $513.15M |
| Other Non-current Assets | $402.52M |
| Liabilities | $4.18B |
| Current Liabilities | $1.47B |
| Accounts Payable | $115.72M |
| Wages | $257.20M |
| Other Current Liabilities | $1.09B |
| Noncurrent Liabilities | $2.71B |
| Equity | $789.18M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $789.18M |
| Liabilities And Equity | $4.97B |
| Net Cash Flow From Operating Activities | $524.08M |
| Net Cash Flow From Operating Activities, Continuing | $524.08M |
| Net Cash Flow From Investing Activities | $436.33M |
| Net Cash Flow From Investing Activities, Continuing | $436.33M |
| Net Cash Flow From Financing Activities | -$305.19M |
| Net Cash Flow From Financing Activities, Continuing | -$305.19M |
| Exchange Gains/Losses | $34.94M |
| Net Cash Flow | $690.16M |
| Net Cash Flow, Continuing | $655.22M |
| Comprehensive Income/Loss | $328.17M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $328.17M |
| Other Comprehensive Income/Loss | $328.17M |
| Other Comprehensive Income/Loss Attributable To Parent | $14.42M |